Selection bias explains seasonal vaccine's protection
- 24 November 2009
- Vol. 339 (nov24 3) , b4972
- https://doi.org/10.1136/bmj.b4972
Abstract
Vaccine efficacy is estimated to be around 80% for trivalent inactivated flu vaccine during seasons when the components closely match circulating strains.1 The surface HA/NA proteins included in the 2008-9 vaccine are antigenically very distant from those of the 2009 pandemic A/H1N1 (pH1N1) virus. Few adults given the 2008-9 vaccine developed neutralising antibody against pH1N1,2 but Garcia-Garcia and colleagues report 73% (95% confidence interval 34% to 89%) cross-protection against pH1N1 with it.3 This finding probably stems from a selection bias associated with their second paradoxical …Keywords
This publication has 4 references indexed in Scilit:
- Cross-Reactive Antibody Responses to the 2009 Pandemic H1N1 Influenza VirusNew England Journal of Medicine, 2009
- Factors Associated With Death or Hospitalization Due to Pandemic 2009 Influenza A(H1N1) Infection in CaliforniaJAMA, 2009
- Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico CityBMJ, 2009
- The prevalence of chronic diseases and major disease risk factors at different ages among 150 000 men and women living in Mexico City: cross-sectional analyses of a prospective studyBMC Public Health, 2009